Over 50 Successful Trade Sales and IPO's
Over 50 Successful Trade Sales and IPO's
Current Portfolio
Past Portfolio
  • Acusphere, USA
    Acusphere, USA

    Drug development injectables

    Acusphere was listed on NASDAQ in 2003.

  • Adnexus Therapeutics, USA
    Adnexus Therapeutics, USA

    Antibody technology platform

    Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.

  • Advanced Accelerator Applications, France
    Advanced Accelerator Applications, France

    Drug development oncology

    AAA was listed on NASDAQ in 2015, then acquired by Novartis for $3.9 billion in 2017.

  • Agensys, USA
    Agensys, USA

    Antibody technology platform

    Agensys was acquired by Astellas for up to $537 million in 2007.

  • Anadys Pharmaceuticals, USA
    Anadys Pharmaceuticals, USA

    Drug development antivirals

    Anadys Pharmaceuticals was listed on NASDAQ in 2004.

  • AnaptysBio, USA
     AnaptysBio,  USA

    Drug development inflammation

     AnaptysBio, Inc.  was listed on NASDAQ in 2017.

  • Anthera, USA
    Anthera, USA

    Drug development cardiovascular

    Anthera was listed on NASDAQ in 2010. 

  • Arcutis Biotherapeutics, Inc
    Arcutis Biotherapeutics, Inc

    Drug development dermatology

     Arcutis was listed on NASDAQ in 2020.

  • ARMO Biosciences
    ARMO Biosciences

    Drug development oncology

    ARMO Biosciences was acquired by Eli Lilly for 1.6 billion in May 2018 .

  • Arpida, Switzerland
    Arpida, Switzerland

    Drug development antibacterials

    Arpida was listed on SIX Swiss Exchange in 2005.

  • Aspreva, Canada
    Aspreva, Canada

    Specialty pharma

    Apreva was listed on NASDAQ in 2005 and acquired by Galenica in 2007 for $915 million.

  • Asthmatx, USA
    Asthmatx, USA

    Medical device pulmonary diseases

    Asthmatx was sold to Boston Scientific for up to $443 million in 2010. 

  • Axovan, Switzerland
    Axovan, Switzerland

    Drug development cardiovascular

    Axovan was acquired by Actelion in 2004 for up to CHF252 million.

  • Barofold, USA
    Barofold, USA

    Protein technology platform

    BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.

  • Basilea Pharmaceutica, Switzerland
    Basilea Pharmaceutica, Switzerland

    Drug development antibacterials and antifungals

    Basilea was listed on SIX Swiss Exchange in 2004.

  • BioControlMedical, Switzerland/Israel
    BioControlMedical, Switzerland/Israel

    Medical device neurology

    BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system.

  • Biovitrum, Sweden
    Biovitrum, Sweden


    Biovitrum was listed on OMX Stockholm in 2006. In 2010 Biovitrum and Swedish Orphan merged forming Swedish Orphan Biovitrum.

  • Brahms, Germany
    Brahms, Germany

    Specialty diagnostics

    Brahms was acquired by ThermoFischer for $470 million in 2009.

  • Cardion, Germany
    Cardion, Germany

    Drug discovery inflammation

    Cardion was acquired by Roche in 2003.

  • ChemoCentryx, USA
    ChemoCentryx, USA

    Drug development inflammation

    ChemoCentryx was listed on NASDAQ in 2012.

  • China Nuokang, China
    China Nuokang, China

    Specialty pharma

    China Nuokang was listed on NASDAQ in 2009.

  • Corgentech, USA
    Corgentech, USA

    Drug development cardiovascular

    Corgentech was listed on NASDAQ in 2004.

  • Corvidia Therapeutics
    Corvidia Therapeutics

    Drug development cardiovascular

    Corvidia was acquired by Novo Nordisk for up to $2.1 billion in 2020.

  • Curetis, Germany
    Curetis, Germany


     Curetis was listed on Euronext in 2015 and then merged with  NASDQ listed OpGen in 2019.

  • Cytokinetics, USA
    Cytokinetics, USA

    Drug development cardiovascular

    Cytokinetics was listed on NASDAQ in 2004.

  • Cytos Biotechnology, Switzerland
    Cytos Biotechnology, Switzerland

    Vaccine technology platform

    Cytos was listed on SIX Swiss Exchange in 2002.

  • Delenex Therapeutics, Switzerland
    Delenex Therapeutics, Switzerland

    Antibody technology platform

    Delenex was acquired by Cell Medica in 2016.

  • Eiger BioPharmaceuticals
    Eiger BioPharmaceuticals

    Drug development orphan diseases

    Eiger BioPharmaceuticals was listed on NASDAQ in 2016.

  • Ellipse Technologies, USA
    Ellipse Technologies, USA

    Medical device orthopedic implants

    Ellipse Technologies was acquired by NuVasive (Nasdaq: NUVA) in 2016.

  • Enanta Pharmaceuticals, USA
    Enanta Pharmaceuticals, USA

    Infectious diseases

     Enanta was listed on NASDAQ in 2013.

  • Esbatech, Switzerland
    Esbatech, Switzerland

    Drug development ophthalmology

    Esbatech was acquired by Alcon (Novartis) for up to $589 million. 

  • Gemin X, Canada
    Gemin X, Canada

    Drug development oncology

    Gemin X was acquired by Cephalon for $225 million in 2003.

  • Homology Medicines, USA
    Homology Medicines, USA

    Drug development genetic diseases

     Homology was listed on NASDAQ in 2018.

  • Icagen, USA
    Icagen, USA

    Drug development inflammation

    Icagen was listed on NASDAQ in 2004.

  • Infinity Pharmaceuticals, USA
    Infinity Pharmaceuticals, USA

    Drug development oncology

    Infinity Pharmaceuticals was listed on NASDAQ in 2006. 

  • Interventional Spine, USA
    Interventional Spine, USA

    Percutaneous spine implants

     Interventional Spine was acquired DePuy Synthes in 2017.

  • Kolltan Pharmaceuticals, USA
    Kolltan Pharmaceuticals, USA

    Drug development oncology

    Kolltan Pharmaceuticals was acquired by Celldex for up to $235 million.

  • Lifeline Scientific, USA
    Lifeline Scientific, USA

    Medical device transplantology

    Lifeline Scientific was listed on AIM London in 2008. 

  • Mediservice, Switzerland
    Mediservice, Switzerland

    Drug distribution

    Mediservice was acquired by Galenica in 2007.

  • Micromet, Germany/USA
    Micromet, Germany/USA

    Drug development oncology

    Micromet was listed on NASDAQ in 2003 and subsequently acquired by Amgen for $1.16 billion.

  • Micrus Endovascular, USA
    Micrus Endovascular, USA

    Medical device neurology

    Micrus was listed on NASDAQ in 2005 and acquired by J&J /DePuy in 2010.

  • Mpex, USA
    Mpex, USA

    Drug development pulmonary diseases

    Mpex was acquired by Axcan in 2011. 

  • mtm Laboratories, Germany
    mtm Laboratories, Germany

    Diagnostics cervical cancer

    mtm was acquired by Roche for up to EUR19 million in 2011. 

  • Newron Pharmaceuticals, Italy
    Newron Pharmaceuticals, Italy

    Drug development neurology

    Newron was listed on SIX Swiss Exchange in 2006.

  • Northstar Neurosciences, USA
    Northstar Neurosciences, USA

    Medical device neurology

    Northstar was listed on NASDAQ in 2006. 

  • Ophthotech, USA
    Ophthotech, USA

    Drug development ophthalmology

    Ophthotech was listed on NASDAQ in 2013.

  • Panomics, USA
    Panomics, USA

    Molecular biology platform

    Panomics was acquired by Affymetrix for $73 million in 2008.

  • Paratek Pharmaceuticals, USA
    Paratek Pharmaceuticals, USA

    Drug development antibacterials

     Paratek was listed on NASDAQ in 2014.

  • PharmaSwiss, Switzerland
    PharmaSwiss, Switzerland

    Specialty pharma

    PharmaSwiss was acquired by Valeant for EUR350 million in 2009. 

  • Precimed, Switzerland/USA
    Precimed, Switzerland/USA

    Medical device surgical instruments

    Precimed was acquired by GreatBatch for $125 million in 2008.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171